Healthcare Industry News: Locus Pharmaceuticals
News Release - January 11, 2010
Viamet Pharmaceuticals Names William Moore, Ph.D. as Chief Scientific Officer
Pharmaceutical Company Developing Best in Class Metalloenzyme Inhibitors Adds Industry VeteranRESEARCH TRIANGLE PARK, N.C.--(HSMN NewsFeed)--Viamet Pharmaceuticals, Inc., a pharmaceutical company developing novel, best in class metalloenzyme inhibitors, announced today that William Moore, Ph.D. has joined the company as Chief Scientific Officer.
Dr. Moore has 21 years of pharmaceutical research and development experience, primarily in early-stage companies. Prior to joining Viamet, he was Chief Scientific Officer and Vice President of Research and Development at Locus Pharmaceuticals, which transitioned from a start-up chemistry technology platform company to an oncology development stage business under his leadership. Prior to Locus, he was Vice President of Target Discovery and Validation at Axys Pharmaceuticals, where he guided the Genomics and Genetics Division into cancer target discovery and integrated the group into a multi-site drug development organization. While at Arris Pharmaceuticals, he led the molecular biology, protein expression, high through-put screening, genomics, enzymology and pharmacology groups that discovered and validated a proprietary zinc-based small molecule enzyme inhibitor technology.
He started his career at Marion Merrell Dow Research Institute following faculty and post-doctoral appointments in Biochemistry at Cornell University Medical College. Dr. Moore received his Ph.D. in Chemistry from Brown University (with a focus on the inhibition of metalloenzymes) and a B.Sc. from Southeastern Massachusetts University.
“We are thrilled to have a seasoned veteran like Bill join our team,” said Robert Schotzinger, CEO of Viamet. “His experience working with the class of drugs on which Viamet is focused – metalloenzyme inhibitors – along with his extensive experience managing collaborations will be critical as we continue to advance our technology, engage in strategic partnerships and move our clinical programs forward.”
“This is an exciting time to join Viamet,” said Dr. Moore. “The company is rapidly moving its products closer to commercialization while enhancing the value of its proprietary Metallophile® Technology. The Metallophile® Technology is a powerful resource to rapidly and cost-effectively develop metalloenzyme inhibitors with improved efficacy, safety and pharmacokinetics. Viamet is poised for success and I look forward to being a critical member of the team.”
About Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals discovers and develops novel, best in class inhibitors of key metalloenzymes via an innovative and proprietary metal-binding approach, the Metallophile® Technology. Viamet’s disruptive Metallophile™ Technology is based on its world-class expertise in bioinorganic chemistry and metalloenzymes and allows Viamet to identify validated metalloenzyme targets with high therapeutic and commercial potential, leverage existing metalloenzyme inhibitors as the basis for its novel analogs, and rapidly and cost-effectively generate superior compounds by optimizing the metal-binding component of existing inhibitors. Viamet is based in the Research Triangle Park region of North Carolina.
Source: Viamet Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
